A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Patients with Castration Resistant Prostate Cancer

INTRODUCTION: Pazopanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. In this randomized open label phase II study, pazopanib alone or in combination with bicalutamide was evaluated in chemotherapy-naive castration resistant prostate cancer (CRPC) patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Sridhar, Srikala S., Joshua, Anthony M., Gregg, Richard, Booth, Christopher M., Murray, Nevin, Golubovic, Jovana, Wang, Lisa, Harris, Pamela, Chi, Kim N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4259891/
https://ncbi.nlm.nih.gov/pubmed/24993934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.06.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados